All Industries

Comcast to Connect Thousands of Homes and Businesses in Madera County to High-Speed Internet

Comcast California

Comcast is connecting more than 2,200 previously unserved homes and businesses across Madera County, California to reliable, high speed, symmetrical Internet by expanding its network to the region, enhancing digital infrastructure, promoting economic growth, and positioning residents and local businesses for success in an increasingly digital world. The network expansion brings residents and businesses in Madera, Chowchilla and other nearby communities, Internet, mobile, entertainment and security services from Xfinity and Comcast Business services to residents and businesses for the first time. The expansion is made possible by a nearly $17 million Federal Funding Account (FFA) grant from the California Public Utilities Commission (CPUC) and private funding by Comcast. Comcast also recently announced it has received an additional $26 million FFA grant to expand its fiber-rich network in Tulare County, which will bring broadband services to nearly 6,200 unserved locations by early 2026, continuing Comcast’s efforts to help close the digital divide in the Central Valley. “I’m thankful to Comcast and the CPUC for their partnership and their continued investments within our great community to bring digital access for our students, families, seniors and businesses to thrive,” said Supervisor Jordan Wamhoff, Madera County Board of Supervisors. “These investments will help bridge the digital divide many Madera County residents experience and help enhance the overall quality of life for our rural communities.” “The CPUC’s decision to award Comcast the Madera County FFA grant builds on our continued efforts in working tirelessly to close the digital divide across the Central Valley,” added David Tashjian, Regional Senior Vice President of Comcast California. “This expansion will support our ongoing network expansion efforts in the Central Valley, in cities such as Biola, Planada, Caruthers, Le Grand and Gustine. We thank the CPUC for this public-private partnership as we continue to work together to increase digital equity within unserved communities and connect people and businesses to what matters most.” Residents and businesses can visit Xfinity.com/mytown and enter their addresses for additional details on construction timing and upcoming service availability. A Network You Can Trust to be Reliable, Fast and Secure Comcast’s state-of-the-art network is built to enable residents and businesses to thrive in today’s constantly connected world. Madera County joins the more than 63 million homes and businesses across the country to have access to a network that is trusted by essential community organizations like hospitals, schools, transportation systems and first responders, and federal agencies like the Department of Defense and FEMA. It delivers multi-gigabit Internet speeds, 99.9 percent reliability and security built in from the ground up to keep customers safe from cyber threats. Introducing Xfinity for Consumers Comcast’s residential services are marketed under the Xfinity and NOW and brands, and consumers in Madera County will be able to take advantage of Xfinity’s and NOW’s full suite of products, including Internet, video, mobile, voice and home security. With multi-gigabit Internet speeds, powerful WiFi that reaches every corner of the home, and super-responsive connections with low lag available with its plan, customers have a great experience using their connected devices to stream their favorite sports and entertainment content, video chat with coworkers and friends, learn from home or simply surf the web. Comcast Business to Power Madera County’s Workforce For local businesses, Comcast Business offers a suite of connectivity, communications, networking, cybersecurity, wireless, and managed solutions to help organizations of all sizes achieve their business goals. Industry analysts and associations have consistently recognized Comcast Business as a leader and innovator in flexible, scalable options as well as one of the fastest-growing providers of Ethernet services. About Comcast Corporation Comcast Corporation (Nasdaq: CMCSA) is a global media and technology company. From the connectivity and platforms, we provide, to the content and experiences we create, our businesses reach hundreds of millions of customers, viewers, and guests worldwide. We deliver world-class broadband, wireless, and video through Xfinity, Comcast Business, and Sky; produce, distribute, and stream leading entertainment, sports, and news through brands including NBC, Telemundo, Universal, Peacock, and Sky; and bring incredible theme parks and attractions to life through Universal Destinations & Experiences. Visit www.comcastcorporation.com for more information. Contact Details Jon Koriel +1 925-315-2690 jon_koriel@comcast.com Company Website https://california.comcast.com/

October 17, 2024 12:58 PM Pacific Daylight Time

NeuroSense Advances Plans For Early Commercialization Of Potentially Groundbreaking ALS Treatment In Canada, Targeting A $100M+ Market

Benzinga

By Kyle Anthony, Benzinga NeuroSense Therapeutics Ltd. (NASDAQ: NRSN), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases – such as amyotrophic lateral sclerosis (ALS), Alzheimer's disease and Parkinson's disease – recently announced its plans to file for early commercialization approval for PrimeC, the firm’s leading drug candidate designed to synergistically target several biological mechanisms of ALS, under Health Canada’s Notice of Compliance with Conditions (NOC/c) policy. This submission is backed by promising results from the company’s phase 2b ALS PARADIGM clinical trial and supplementary clinical and preclinical data. ALS Explained ALS is a nervous system disease that affects nerve cells in the brain and spinal cord. The disease causes loss of muscle control, and gradually worsens over time. Often called Lou Gehrig's disease after the baseball player who was diagnosed with it, the exact cause of the disease is still not known. ALS often begins with muscle twitching and weakness in the arm or leg, trouble swallowing or slurred speech. Eventually, ALS affects the control of the muscles needed to move, speak, eat and breathe. There is no cure for this fatal disease. Every year, more than 5,000 people are diagnosed with ALS in the U.S. alone, with an annual disease burden of $1 billion. The number of people living with ALS is expected to grow by 24% by 2040 in the U.S. and European Union. The Efficacy Of NeuroSense’s PrimeC Treatment PrimeC, NeuroSense's lead drug candidate, is a novel extended-release oral formulation with a unique fixed-dose combination of two FDA-approved drugs: ciprofloxacin and celecoxib. PrimeC is designed to synergistically target several biological mechanisms of ALS that contribute to motor neuron degeneration, inflammation, iron accumulation and impaired ribonucleic acid (RNA) regulation. The goal is to inhibit the progression of ALS. NeuroSense reports that PARADIGM, a prospective, multinational, randomized, double-blind, placebo-controlled phase 2b clinical trial of PrimeC in ALS, has demonstrated the drug's efficacy. The trial d emonstrated that PrimeC significantly reduced disease progression (p=0.009) and improved survival rates by 43% compared to placebo, highlighting its potential as a breakthrough therapy for ALS. The trial included 68 participants living with ALS in Canada, Italy and Israel. 96% of the trial participants who completed the 6-month double-blind portion of the trial chose to receive treatment with PrimeC through a 12-month open-label extension. As of June 2024, all participants who completed the 18-month trial treatment duration requested to continue PrimeC, which is provided to them in an Investigator Initiated Trial, not limited to time. The PARADIGM clinical study observed a statistically significant slowing of disease progression in patients who used PrimeC versus placebo, based on the ALS Functional Rating Scale-Revised (ALSFRS-R). The Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS) is the gold standard instrument for evaluating the functional status of patients with ALS. It is used to monitor functional change in a patient over time. NeuroSense reports that most patients enrolled in both the active and placebo arms of the trial were concurrently treated with Riluzole, the ALS standard of care medication, indicating PrimeC slowed disease progression well beyond the level afforded by the FDA-approved ALS drug. The FDA and the European Medicines Agency have granted PrimeC Orphan Drug Designation. Commercialization Of PrimeC In Canada And Worldwide Health Canada’s Notice of Compliance with Conditions (NOC/c) is authorization to market a drug, with the condition that the sponsor undertake additional studies to verify the clinical benefit. As such, this speeds up the time to market for the drug, enabling earlier commercialization. In advancing PrimeC's commercialization potential, NeuroSense plans to submit its regulatory dossier to Health Canada in Q2 2025, with a regulatory decision anticipated by Q1 2026, and NeuroSense estimates the market opportunity for PrimeC in Canada alone to be approximately $100 million to $150 million in annual revenue, reflecting the unmet need for effective ALS treatments. Beyond Canada, NeuroSense plans to pursue regulatory approval in additional global markets as part of its broader strategy to make PrimeC accessible to ALS patients worldwide. Alon Ben-Noon, CEO of NeuroSense, stated, “The Canadian market presents a significant near-term opportunity, with the addressable market for PrimeC valued above $100 million in annual revenue. Securing early commercialization approval in Canada would represent an important milestone, not only to address the unmet need for ALS treatments but also as part of our strategy to drive sustainable growth. With additional markets on our radar, this marks the beginning of what we anticipate will be a long-term revenue-generating opportunity." Looking Forward NeuroSense’s PrimeC has the potential to reshape the landscape for ALS treatment, enhancing the quality of life for individuals around the globe afflicted by this debilitating disease. The promising results from the PARADIGM clinical trial and NeuroSense's commercial advancement plans for the drug indicate that PrimeC may soon be able to benefit ALS patients around the world and potentially position the company to be a leader in treating the disease. Featured photo courtesy of NeuroSense Therapeutics. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

October 17, 2024 02:00 PM Eastern Daylight Time

Image

MetaProp Accelerator at Columbia University Announces 2025 Program and Open Applications Period

MetaProp

MetaProp announced today the launch of applications for the 2025 MetaProp Accelerator at Columbia University, the world's premier PropTech Accelerator based in the heart of New York City. The flagship 22-week program connects up to 8 early-stage startups from around the world to award-winning investors, industry mentors, and diverse real estate, technology, and institutional partners. Entering its milestone 10th year, the MetaProp Accelerator has graduated over 50 startups, which have collectively raised more than $200 million in venture funding and achieved notable exits, including 6 acquisitions by industry leaders such as JLL, Comcast, Realtor.com, and Alarm.com. MetaProp is looking into several timely investment verticals to be represented within its 2025 cohort. Co-Founder and General Partner Zach Aarons commented, “Buildings account for two-thirds of the greenhouse gas emissions in New York City. After Local Law 97 was passed in 2019, it’s become imperative for MetaProp to identify and help grow emerging technologies in the decarbonization sector. In addition to climate tech, we’re looking into PropTech innovations touching artificial intelligence, software for affordable housing, and construction robotics.” The Accelerator provides a direct line into MetaProp’s stakeholders’ collective strength while giving unprecedented access to strategic funding and new enterprise clients worldwide. Detailed benefits include: Up to $250,000 in financing 22-week program focused on driving business growth and accelerated market penetration Curated access and introductions to industry decision-makers, technology pilots, premier sources of investment capital, and international media Free office space in Midtown Manhattan at the PropTech Place innovation hub Participation in exclusive Pilot Days and Demo Days, along with discounted or free attendance at numerous local, national, and international industry events. Pairing with select C-level mentors from MetaProp’s real estate industry mentor network Dedicated MetaProp VC platform services Access to consortium program partners, as well as free goods and services Historically, MetaProp limited partners including CBRE, JLL, Cushman & Wakefield, RXR, and PGIM have been deeply engaged throughout the 22-week accelerator programs. The new 2025 program also includes a renewed partnership with the Real Estate Board of New York (REBNY). REBNY members will have exclusive opportunities to engage with cutting-edge PropTech innovations through events, pilot days, and mentorship programs. Sandhya Espitia, REBNY Chief Operating Officer, stated, "REBNY is proud to support MetaProp's Accelerator and is excited to see the innovative solutions to come out of this year's program. As New York City's premier trade association for the real estate industry, we understand the importance of engaging in PropTech efforts that solve real issues for our city and our industry." MetaProp unveiled the first company in its landmark cohort: BuildrFi, a Miami-based startup transforming the construction industry by simplifying financial workflows and enabling project-based financing. “At BuildrFi, we’re committed to solving one of the industry’s biggest challenges: payment delays,” said Isabel Rodriguez, Founder and CEO at BuildrFi. “We’re honored to be the first company selected for MetaProp’s 2025 Accelerator program. With MetaProp’s unparalleled network of industry leaders and our team’s deep expertise in this category, we’re ready to scale our impact and drive meaningful change across the sector.” The application deadline for the 2025 MetaProp Accelerator at Columbia University is December 31, 2024. Learn more and apply to the new program here: metaprop.com/accelerator About MetaProp MetaProp is a New York-based venture capital firm focused on the real estate technology (“PropTech”) industry. Founded in 2015, MetaProp’s investment team has invested in 175+ technology companies across the real estate value chain. The firm manages multiple funds for both financial and strategic real estate investors that represent a pilot- and test-ready sandbox of 20+ billion square feet across every real estate asset type and global market. The firm’s investment activities are complemented by pioneering community leadership including the PropTech Place innovation hub, MetaProp Accelerator at Columbia University programs, global events including NYC Real Estate Tech Week, and publications Global PropTech Confidence Index and PropTech 101. Contact Details MetaProp Wes Mizell wmizell@metaprop.com Company Website https://www.metaprop.com/

October 17, 2024 01:15 PM Eastern Daylight Time

Minerva Surgical Signs Agreement with Blackmaple Group (BMG) and WHAAPA

Minerva Surgical, Inc.

Minerva Surgical, a manufacturer and distributor of minimally invasive gynecologic technologies, today announced a new strategic partnership with Blackmaple Group, designed to provide access to office-based solutions for its Women’s Health Administrative and Purchasing Alliance (WHAAPA) physician members for the detection and treatment of uterine conditions. The Medical Endoscopy Image Processing System and the Minerva ES Ablation System – both of which will be available to BMG WHAAPA members under this new agreement – are designed to quickly and effectively address causes of Abnormal Uterine Bleeding (AUB) a set of debilitating conditions affecting one in three women. Left untreated, AUB may drive women to withdraw or become absent from family, social, and work activities. Some of these conditions can be life threatening, if not detected early. According to Darin Hammers, CEO of Minerva Surgical, “Integrating hysteroscopy into the office setting enables gynecologists to detect uterine cavity disease earlier and more accurately than using other, less sensitive methods. The Minerva ES endometrial ablation can be performed in the comfort of the office setting, while reducing the cost to the patient. Effectiveness of the Minerva ES has been proven in clinical trials demonstrating procedure safety and long-term avoidance of hysterectomy in over 99% of the patients.” Additionally, Minerva ES is a one-time, non-hormonal, incisionless treatment with the recovery time of 1-2 days. “The agreement with Minerva Surgical is important to Blackmaple Group because it provides WHAAPA members with more options to safely and effectively treat patients in the office setting”, said Dr. Jeff Gold, CEO of BMG. About Minerva Surgical: Minerva Surgical is a Women’s Health company committed to improving women's health and quality of life by providing access to minimally invasive, technologically advanced, and innovative solutions for early detection, treatment, and management of uterine conditions. About Blackmaple Group: founded in 2008 as a consulting firm focused on bringing business rigor to provider group management, the Blackmaple Group (BMG) has grown to become an industry leader in procurement, medical group management and healthcare economics. Under the leadership of its founder Dr. Jeff Gold and COO Marc Cooper, BMG has grown to over 16,000 physician members across the United States and continues to add new clients every day. Contact Details Kevin Tracey +1 855-646-7874 info@minervasurgical.com Company Website https://minervasurgical.com/

October 17, 2024 10:00 AM Eastern Daylight Time

The Great World Race Inaugural Event Features Terminal Cancer Survivor Sean Swarner and Social Media Star and Cancer Advocate Iain Ward, "The King of Chemo"

Ice Cap Adventures

The Great World Race announces its first annual event, launching on November 15th, 2024. This exciting competition invites participants to complete seven marathons on seven continents in seven consecutive days. Beginning at Wolf’s Fang in Antarctica, the 60 runners will then travel to Cape Town in Africa, followed by Perth in Australia. The Great World Race continues with two marathons in Istanbul, spanning both Asia and Europe across the Bosphorus. The final legs will take place in Cartagena, South America, and Miami, North America. Successful finishers will be eligible for The Global Marathon Club, recognizing those who complete all seven marathons in the designated timeframe. Additionally, there will be male and female champions determined by the fastest overall average marathon times across the continents. This year, The Great World Race has partnered with the non-profit charity LUNGevity who are transforming how people are diagnosed and live with lung cancer through research, education and support. LUNGevity will be represented by terminal cancer survivor Sean Swarner. Swarner was given 2 weeks to live as 16 year old, yet 33 years later he is getting ready for the 777 after having already completed the Explorers Grand Slam in 2017, one of only 50 people to ever complete the feat. His feat was all the more impressive given that Sean has only one functioning lung. Sean speaks of the bond he formed with LUNGevity and the community they help: “I spoke at the LUNGevity Hope Summit, an amazing event for lung cancer survivors and their caregivers. My immediate reaction was – this is my community! As a two-time cancer survivor, I understood what the attendees were going through, and decided then to help raise awareness for lung cancer and help raise funds for research. The Great World Race is the perfect platform to reach a whole new audience and get them involved. Please follow me and support the 1 in 18 people who will be diagnosed with lung cancer in their lifetime.” Becs Gentry, a Peloton instructor and marathon runner with a personal best of 2:32, is a prominent figure in the women's race. Based in New York City, Becs finished 4th in the 2021 British Olympic Trials, narrowly missing her chance to compete in the Olympics. Ashley Paulson, a two-time champion and record holder of the Badwater ultramarathon, will also race in Antarctica on November 15th. Additionally, Chirine Njeim from Lebanon brings impressive credentials, having represented her country at three Winter Olympics in skiing and at the marathon during the Beijing Summer Olympics. In the men's event, David Kilgore (USA) has carved out a reputation as one of the best in the world of endurance sport and ultrarunning. Two other athletes aim to achieve remarkable feats as they strive to be the oldest and youngest individuals to complete marathons on all seven continents within a week. Dan Little, an 81-year-old from Oklahoma, and Merrick Chernett, an 18-year-old from Michigan, are both seeking to make history. Notable participants include Alvaro Nunez, originally from Spain, who came to the United States on a tennis scholarship and has since become a successful ultramarathon runner, best-selling author, and entrepreneur based in Miami. Cole Brecka, son of well-known human biologist Gary Brecka, the man Dana White credited with changing his life and his health turnaround, will also join the event and aims to use the knowledge of his father in the science and nutrition space to turn himself into the first Ultimate Human Athlete. The Great World Race has gained international attention on social media, particularly with the involvement of social media creator and cancer awareness advocate, Iain Ward, known as @thekingofchemo. After being diagnosed with terminal brain cancer in 2020, Iain has dedicated his life to raising funds for cancer through athletic events. His inspiring journey and engaging posts have attracted over 12 million followers across social media platforms. Audiences are drawn to his ability to transform a tragic diagnosis into a proactive mission, combined with his witty humor. Iain is participating in the Great World Race to benefit the American Cancer Society by seeking corporate sponsorships and donations. When asked about this initiative, Iain stated: “My terminal brain cancer diagnosis has given me absolute clarity: I want to use the time I have left to laugh in cancer’s ugly face by raising more money for cancer research than anyone ever has. We want to break the world record of $3,000,000, starting with the Great World Race. You don’t even have to donate: The bigger the channel gets, the more sponsorships we get, and the more money goes to charity. But I can’t do this without you, and I need each and every one of you reading this to follow right now. It only takes seconds and it will help raise money for the 1 in 2 people who will get cancer in their lifetime. So do it for your friends, your family, everyone you know who is affected by cancer.” “I'm delighted to be joining forces with LUNGevity, the work they do is outstanding in helping their community through difficult times, sometimes when people have lost hope. It's also great to be working with all participants embarking on this outstanding physical and mental challenge. Sean's story is one that illustrates how you should never give up hope, no matter the circumstances and his adventures have shown what can be done when you believe in yourself. Iain is an incredible character, his ability to take a positive view on an extremely tough diagnosis is inspiring. We should all take a leaf out of his book and make the most out of life, health is too often a commodity we all take for granted”, said David Kelly, CEO of Ice Cap Adventures and Great World Race event director. For additional information or interest in joining the 2025 race, visit thegreatworldrace.com. To check out the great work LUNGevity do, visit HERE: www.LUNGevity.org/ To donate to Iain’s fundraiser for American Cancer Society visit HERE: https://secure.acsevents.org/site/STR?pg=entry&fr_id=108295 About the Great World Race The Great World Race, organized by Ice Cap Adventures Limited, is the only 7-continents athletics event taking place in 2024. The CEO of the company and Race Director of the event, David Kelly, is a medical doctor and former Irish international athlete. David will be accompanied by a traveling support team of top professionals, all with extensive international experience in the polar regions and in round-the-world events. Among them are photographers and cameramen who will ensure every special marathon moment is captured for competitors and global media. Contact Details Ice Cap Adventures Limited David Kelly david@icecapadventures.com Company Website https://thegreatworldrace.com/

October 17, 2024 09:04 AM Eastern Daylight Time

Image

Quantum Resistant Ledger (QRL) Strikes Key Industry Partnerships, Fortifying Its Position As Quantum Computing Era Nears

Benzinga

By Gerelyn Terzo, Benzinga Chinese researchers recently accomplished what they claim was the world’s first successful quantum attack on popular encryption algorithms. While the first cohort of thousands of quantum computers isn’t expected to come onto the scene until at least 2030, their problem-solving capabilities already appear to have become a reality. Some cutting-edge companies and projects like Quantum Resistant Ledger (QRL) already recognize the potential threats this technology could pose as it develops. QRL was designed to protect burgeoning technologies – including blockchains and cryptocurrencies – from any future threats that quantum computing may pose. In fact, the company shares that 99% of blockchains and cryptocurrencies are considered vulnerable in a post-quantum computing world, as blockchains and cryptocurrencies continue to remain heavily dependent on quantum-insecure cryptography. To strengthen its post-quantum preparedness, QRL has been striking key industry partnerships and integrations of late to serve the company’s vision for the foreseeable future. Chief among these collaborations is with the PKI Consortium. Founded in 2013, the PKI Consortium is a group dedicated to the future of Internet security, boasting high-profile members that, in addition to QRL, include Dell Technologies (NYSE: DELL), Fox Crypto and card giant Visa (NYSE: V), among many others. Not only is QRL a member of the organization, but it’s also one of the sponsors of an upcoming event hosted by the PKI Consortium. In early 2025, PKIC will host the Post Quantum Cryptography Conference in Austin, Texas, sponsored by QRL alongside peers such as Noreg, Entrust, PQ Shield, SSL.com, KeyFactor and HID. This sponsorship allows QRL the distinct opportunity to collaborate with other expert representatives from the likes of the National Institute of Standards and Technology (NIST) as well as other industry leaders such as Google (NASDAQ: GOOG), IBM (NYSE: IBM) and Honeywell (NASDAQ: HON), to name a few. To register for this event, click here. PKI Consortium chair Paul van Brouwershaven stated, "We are delighted to welcome the QRL Foundation as an Innovator sponsor of the hybrid Post-Quantum Cryptography Conference on Jan. 15 - 16, 2025 at the University of Texas at Austin. Their commitment to advancing quantum-resistant technologies supports the collaborative effort needed to future-proof our cryptographic systems, ensuring a resilient and secure digital landscape for all." This partnership is only scratching the surface of all that the QRL team is doing behind the scenes and the important industry relationships it is building along the way. Blockchain industry participants who are interested in joining the project can learn more about all that QRL has to offer here. QRL’s Strategic Relationship Building Among the other strategic partnerships QRL has inked is its deal with the Linux Foundation, more specifically, its Post-Quantum Cryptography Alliance (PQCA) arm. Known as a neutral platform for developers to code and scale open technology, the Linux Foundation launched PQCA earlier this year to advance post-quantum cryptography and drive its adoption. Through this alliance, QRL joins in sharing its post-quantum cryptographic expertise to participate in the building of infrastructure of the future with its peers, which include the likes of Amazon Web Services (NASDAQ: AMZN), Google and Nvidia (NASDAQ: NVDA), to name a few. Through projects like Open Quantum Safe and Post-Quantum Code Package, PQCA deems its members as “essential to the success of the Foundation” and “instrumental in steering the alliance direction.” As one of the industry’s most loyal partners, QRL also continues to support The League of Entropy, a collaboration that delivers publicly verifiable decentralized randomness as a service (DRS), paving the way for a wide range of applications. As a play on power in numbers, this group shifts the randomness beacon focus from individual entities to a group mentality, where the benefits and security can potentially be more pervasive. QRL’s 2025 Pipeline With the power of its partnerships at its disposal, QRL is looking ahead to Q1 2025 for events such as the public release of its proof-of-stake (PoS) network, which as of early 2024 was in the beta testnet phase, aka Test Zond. This platform boasts compatibility with the industry standard – the decentralized Ethereum Virtual Machine (EVM) – and QRL will also be seeking new partnerships for which grants are available through its overarching foundation to enhance the technology and its reach. What that means is that developers desiring to build on Layer-1, the foundational layer of the blockchain network, will have the option to build on one that’s quantum secure from the bottom up – QRL. As always, security remains paramount for the QRL team, which has been prioritizing a series of audits before any definitive launch of the platform. The timing couldn’t be better. Indications suggest there might already be a quantum computer threatening to abscond with Bitcoin funds. Anecdotal evidence shows wallet and digital asset movements from legacy Satoshi Nakamoto-era wallets to crypto exchanges involving millions of dollars worth of Bitcoin. While there’s no hard evidence of QC involvement, it’s a good reminder of where vulnerabilities remain in a system that has already been demonstrated to have a target on its back from nefarious actors. The rise of quantum computing will have implications for the crypto sector at large, and those who stick their proverbial heads in the sand could be left behind. Astute industry participants who would like to join in the preparation should visit the QRL today. Featured photo by geralt on Pixabay. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

October 17, 2024 08:35 AM Eastern Daylight Time

Image

Bitdeer (Nasdaq: BTDR) Advances Roadmap With Successful Testing Of Its Energy-Efficient SEAL02 Bitcoin Mining Chip

Benzinga

By Gerelyn Terzo, Benzinga With bullish predictions for the Bitcoin price once again swirling, some experts believe BTC miners may experience increased demand. Six months have passed since the Bitcoin halving, and if history is any indication, the BTC price could have greater upside potential both in the near and long term. Bitdeer Technologies Group (NASDAQ: BTDR) is gearing up to provide the Bitcoin mining community with its latest technology, which is increasingly more energy efficient with every passing quarter. As part of its commitment to transparency, the company has shared the successful testing of SEAL02, the latest in a series of Bitcoin mining chips for which it has outlined a series of releases and updates. Bitdeer has developed its SEAL02 chips in partnership with leading semiconductor company TSMC. After receiving what are known as initial tape-out wafers from TSMC in mid-September, Bitdeer has ushered in results, which indicated an initial verification and prototype of 13.5J/ETH efficiency at low voltage, ultra power saving mode – an encouraging result for the energy-intensive process of BTC mining. SEAL02 chips are to be integrated into Bitdeer’s SEALMINER A2 mining machines, the mass production of which is planned for November. However, its SEALMINER A1 machines, which also lend themselves to better efficiency, are still in play, too, with mass production and distribution now planned for Q4 2024. Hashrate represents the computational power of a mining rig, and the number of joules per unit of compute (J/TH) represents the efficiency. Meanwhile, Bitdeer remains in the R&D phase for its third-generation chip, SEAL03, which is expected to continue to unfold with the product release milestone within view. While the performance of the SEAL02 chips was just confirmed from testing tape-out wafers from TSMC, the SEAL 03 prototype is scheduled for a similar process by year-end 2024 amid an improved chip efficiency of 10 J/TH. Bitdeer Chief Business Officer Linghui Kong stated, “We are thrilled about achieving SEALMINER’s power efficiency target as reflected in our roadmap. Our ongoing commitment to R&D is making possible innovative and superior solutions that will set new benchmarks for efficiency and transparency to benefit the wider mining ecosystem.” Bitdeer Envisions Further Technological Breakthrough, Eyes AI And HPC Segments As Bitdeer’s SEAL02 chips move forward to the next phase, the company continues to advance its roadmap as planned. Boasting a total hashrate under management of 17.1 EH/s, Bitdeer also oversees 167,000 mining machines. Bitdeer has mined 164 BTCs as part of its proprietary mining within a total data center portfolio of 895 MW. The company said its advanced chip design will catapult its SEALMINER product line to triple the energy efficiency of the legacy ASIC miners by H2 2025. Additionally, as Bitdeer engineers continue to innovate and perfect chip design, they expect new technological breakthroughs, the benefits of which are expected to spill over from Bitcoin mining into other segments such as artificial intelligence and high-performance computing (HPC). Bitdeer has arranged its roadmap so that new chip designs are released nearly every other quarter as it continues to strive for greater energy efficiency for the wider industry. Investors who are interested in learning more about Bitdeer’s financial performance and future growth plans can do so here. Featured photo by TheDigitalArtist on Pixabay. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

October 17, 2024 08:30 AM Eastern Daylight Time

Image

Active Traders And Investors Could Find Significant Balance Boosts During Robinhood's Upcoming HOOD Week

Benzinga

By Anthony Termini, Benzinga Beginning Oct.16 and continuing through the 27th, Robinhood Markets, Inc. (NASDAQ: HOOD) will be offering special incentives to encourage active traders and investors to transfer accounts to the company’s commission-free investment platform. The strategic initiative is intended to attract new customers and encourage current account holders to transfer assets from other brokers into a Robinhood account. HOOD Week Is A Limited Promotion Offering Unlimited Rewards The main questions active traders and buy-and-hold investors need to ask themselves about the 12-day HOOD Week event are why am I trading or investing and what’s in it (transferring accounts) for me? The numbers are pretty straightforward. Traders and investors who open and fund an account at Robinhood between Oct. 16 and 27 will get a cash bonus added to their account. For brokerage transfers of taxable individual or joint accounts, the bonus is 1% of the transferred balance. For those same accounts with a minimum margin balance of $10,000, the bonus is 2%. However, individuals who make use of Robinhood’s vast ecosystem reap the most rewards. Individuals who make a transfer to their Robinhood IRA with a Robinhood Gold subscription receive a 3% bonus, excluding rollovers. In the world of investing, 1%, 2%, or 3% are big and notable numbers, the company says. Not to mention, the HOOD Week bonuses have no limit. Who Benefits From Robinhood’s HOOD Week Bonuses? Since the bonuses are uncapped, it might be easy to assume that the main beneficiaries of the HOOD Week promo are active traders or traditional investors with a large investment balance. The more zeros in the account balance the bigger the bonus. However, even new investors and traders could be well-positioned to benefit from these bonuses. That’s why investors should know that the Robinhood HOOD Week incentives are available to all customers. To claim the uncapped bonus, investors can transfer stocks, cash, options, margin balances, IRAs, and any of the other types of securities that are available on the Robinhood platform, including cryptocurrencies. It’s important to note that account transfers that move into Robinhood’s Gold subscription service enjoy even more benefits. Those include Morningstar’s premium in-depth stock research reports, instant access to transfers up to $50,000, a 4.5% APY on idle cash, and a highly discounted margin rate (8% vs. 12%). So traders and investors looking for a boost to their accounts might consider moving money over to Robinhood during the HOOD Week incentive period. The important deadline is October 27. Transfers made by then are eligible to claim an uncapped bonus on stocks, cash, IRAs, and more. Click here for more information. Featured photo by Gerd Altmann from Pixabay. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. Disclosures: Investing is risky. Bonus offers subject to terms and conditions, visit robinhood.com/hoodweek for more information. Margin is not suitable for all investors. Robinhood Gold is offered through Robinhood Gold LLC and is a subscription offering services for a fee. Brokerage services offered through Robinhood Financial LLC (member SIPC), a registered broker dealer. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

October 17, 2024 08:25 AM Eastern Daylight Time

Image

AGC Biologics Seattle Achieves Approval for all 2024 Biologics License Applications from U.S. Food and Drug Administration, Concluding Pre-License Inspection

AGC Biologics

AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced the U.S. Food and Drug Administration (FDA)’s approval of a third Biologics License Applications (BLA) from the March 2024 inspection of the company’s Seattle facility. The closure of this inspection and final BLA approval resulted in each of the three commercial products evaluated being approved for commercial production – a regulatory compliance and quality milestone for the site. The Seattle CDMO facility welcomed the FDA in March 2024 for an intensive week of three product inspections. The approved products include two FC-fusion proteins and a monoclonal antibody (mAb). One of the FC-fusion proteins is focused on treating non-muscle invasive bladder cancer; the other is designed to treat age-related neovascular Macular Degeneration (nAMD) and other serious retinal diseases. The mAb product targets chronic-versus-host disease (GVHD). The series of 2024 BLA approvals continues a trend of successful regulatory milestones for the AGC Biologics Seattle site. The FDA has approved four biologics products manufactured at this facility in the last two years. AGC Biologics received commercial approval at the end of 2022 for a mAb product targeting type 1 diabetes (T1D), the first and only treatment of its type at the time of approval. “Performing an agency inspection for three products simultaneously is not easy and I am extremely proud of this result. We took on the challenge and helped ensure every product evaluated achieved commercial approval this year,” said Jose Gonzalez, General Manager, AGC Biologics Seattle. “This is a tremendous achievement for our site. For our partners bringing lifesaving treatments to patients, it is pivotal for their manufacturing partner to maintain regulatory compliance and a high level of product quality to help them reach commercial success. This is a shining example of AGC Biologics’ Seattle ability to do that.” AGC Biologics operates multiple mammalian cGMP manufacturing lines of various scales at its Seattle site, which serves as a center of excellence for formulation and employs the latest fed-batch and perfusion manufacturing processes. In the past year, AGC Biologics Seattle has also expanded to include a new microbial-based manufacturing line system and a state-of-the-art 67,000 sq. ft. GMP-compliant warehouse to further enhance the quality, efficiency and operational excellence of the site. To learn more about AGC Biologics’ protein biologics manufacturing site in Seattle, visit www.agcbio.com/facilities/seattle. For more information on the company’s end-to-end global CDMO services in the U.S., Europe and Japan visit www.agcbio.com. About AGC Biologics: AGC Biologics is a leading global biopharmaceutical Contract Development and Manufacturing Organization (CDMO) with a strong commitment to delivering the highest standard of service as we work side-by-side with our clients and partners, every step of the way. We provide world-class development and manufacture of mammalian and microbial-based therapeutic proteins, plasmid DNA (pDNA), messenger RNA (mRNA), viral vectors, and genetically engineered cells. Our global network spans the U.S., Europe, and Asia, with cGMP-compliant facilities in Seattle, Washington; Boulder and Longmont, Colorado; Copenhagen, Denmark; Heidelberg, Germany; Milan, Italy; and Chiba, Japan. We currently employ more than 2,500 Team Members worldwide. Our commitment to continuous innovation fosters the technical creativity to solve our clients’ most complex challenges, including specialization in fast-track projects and rare diseases. AGC Biologics is a part of AGC Inc.’s Life Science Company. The Life Science company runs more than 10 global facilities focused on biopharmaceuticals, advanced therapies, small molecule active pharmaceutical ingredients, and agrochemicals. To learn more, visit www.agcbio.com. Contact Details AGC Biologics Nick McDonald +1 425-419-3555 nmcdonald@agcbio.com Company Website https://www.agcbio.com/

October 17, 2024 05:57 AM Eastern Daylight Time

1 ... 20 21 22 23 24 ... 3763